Dupilumab, a fully human monoclonal antibody that targets the interleukin (IL)‐4 receptor alpha subunit (IL‐4Rα) blocking IL‐4 and IL‐13 signaling, has revolutionized the treatment landscape for several type 2 (T2) inflammatory diseases, including severe asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), atopic dermatitis (AD), and eosinophilic esophagitis (EoE) [1]. The gene discussed is IL13; the disease is chronic rhinosinusitis with nasal polyps.